Bruce Strober

Yale University — United States

Immunology and Microbiology · Life Sciences

65h-index19.0kcitations479works2.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Psoriasis: Treatment and Pathogenesis(357), Dermatology and Skin Diseases(133), Health Systems, Economic Evaluations, Quality of Life(75), Autoimmune Bullous Skin Diseases(70), Pharmaceutical studies and practices(68)

Publications477 total

Summary of Research: Apremilast in Japanese Patients with Palmoplantar Pustulosis: A Randomized, Phase 3 Trial
Dermatology and Therapy·2025Open Access
Laboratory monitoring in patients with moderate to severe plaque psoriasis
Journal of Dermatological Treatment·2025Open Access
EPH126 Higher Mortality for Generalized Pustular Psoriasis Compared With Plaque Psoriasis Highlights the Need for Improved Treatments: Insights From a Meta-Analysis
Value in Health·2025
CO144 Improvements in Scalp Outcomes With Roflumilast Foam 0.3% for Psoriasis of the Scalp and Body From the Phase 3 ARRECTOR Trial
Value in Health·2025
Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial
Journal of the European Academy of Dermatology and Venereology·2025· 3 citedOpen Access
Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitors
Journal of the American Academy of Dermatology·2025Open Access
Real-World Effectiveness of Guselkumab in Patients With Psoriasis: Data From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
SKIN The Journal of Cutaneous Medicine·2025Open Access
Individual Clinical Response Trajectories to Lebrikizumab in Atopic Dermatitis: A Cluster Analysis
SKIN The Journal of Cutaneous Medicine·2025Open Access
Long-Term Durability and Stability of Amlitelimab Efficacy in Adults With Moderate-to-Severe Atopic Dermatitis: 52-Week Post Hoc Analysis of the STREAM-AD Phase 2b Trial
SKIN The Journal of Cutaneous Medicine·2025Open Access
Real-World Comparative Effectiveness of Deucravacitinib vs Apremilast at 6 Months for Plaque Psoriasis: Skin Clearance Outcomes From the RePhlect Study
SKIN The Journal of Cutaneous Medicine·2025Open Access
Durable maintenance of EASI-90 with amlitelimab in adults with moderate-to-severe atopic dermatitis: 52-week results from the STREAM-AD phase 2b trial
SKIN The Journal of Cutaneous Medicine·2025Open Access
Real-World Clinician- and Patient-Reported Outcomes and Treatment Persistence Following Bimekizumab Initiation in Patients with Psoriasis: 6-Month Results from the PPD CorEvitas Psoriasis Registry
SKIN The Journal of Cutaneous Medicine·2025Open Access
Comparison of All-Cause Mortality in Generalized Pustular Psoriasis and Plaque Psoriasis: A Systematic Review and Meta-Analysis
Dermatology and Therapy·2025Open Access
104 EVERLAST-A: A Phase 2a Study Design of ORKA-001, a Novel Half-Life Extended IL-23p19 Monoclonal Antibody for Plaque Psoriasis
Journal of Investigative Dermatology·2025
106 SPECTREM: Guselkumab Demonstrates Consistent Significant Clearance Across the Full Range of Low Body Surface Area, Moderate Psoriasis With Special Sites Involvement
Journal of Investigative Dermatology·2025
Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results from the DERMIS Phase III Trials
Dermatology and Therapy·2025Open Access
In Memoriam: Wayne Peter Francis Gulliver, MD, FRCPC (March 4, 1958-September 5, 2025)
Journal of the American Academy of Dermatology·2025
Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical Trials
Dermatology and Therapy·2025Open Access
RWD224 PREVALENCE AND ADVANCED SYSTEMIC TREATMENT PRESCRIPTION PATTERNS FOR SCALP PSORIASIS IN THE REAL-WORLD DERMATOLOGY SETTING IN THE UNITED STATES
Value in Health Regional Issues·2025
How Janus kinase selectivity impacts efficacy and safety of abrocitinib for atopic dermatitis: an expert consensus panel
Dermatology Online Journal·2025Open Access
page 1 of 24Next →

Frequent Co-authors

Mark Lebwohl(21), Kenneth B. Gordon(17), Alan Menter(14), Kim Papp(14), Craig L. Leonardi(12), Richard G. Langley(10), Alice B. Gottlieb(10), Alexa B. Kimball(9), Joel M. Gelfand(9), Neil J. Korman(9), Jashin J. Wu(9), April W. Armstrong(8), Daniel H. Kaplan(7), Amy S. Paller(7), Darío Kivelevitch(6), Benjamin K. Stoff(6), Cody Connor(6), Kelly M. Cordoro(6), Dawn Marie R. Davis(6), Boni E. Elewski(6)